TreeFrog Therapeutics Presents Delivery Strategy for Next Generation 3D Cell Therapy Format for Parkinson's Disease at the 28th Annual ASGCT Meeting in New Orleans
BORDEAUX, France--(BUSINESS WIRE)--TreeFrog Therapeutics, a French biotech specializing in cell therapy is the first company to present a clinical-ready delivery strategy for 3D microtissues cell therapy. The validated approach was demonstrated for their 3D neural microtissues cell therapy treatment for Parkinson's disease.
"I am excited to present a validated strategy for 3D format cell therapy for Parkinson's disease which took 4 years of development and overcomes challenges to ensure homogenization and accurate dose delivery."
Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's disease. It is a progressive disease characterized by the loss of dopaminergic neurons with a mix of motor symptoms (bradykinesia, rigidity, resting tremor) and non-motor symptoms (cognitive deficits, mood disorders, fatigue). Current treatments provide symptomatic relief only. There is a huge unmet need with a prevalence that has doubled in the last 25 years to an estimated 10 million sufferers, and it is expected to double again by 2050 1, 2.
Research into cell replacement strategies for Parkinson's disease has been ongoing for decades and the promise of cell therapy in the disease has resulted in a dynamic clinical trial landscape. Since 2021, when there were 5 trials in Parkinson's disease, there have been 15 new trials initiated or planned 3.
Most cell therapies rely on single-cell suspensions which, while still holding promise, face specific challenges such as elevated cell death due to anoikis. Next generation 3D formats such as the neural microtissues in development by TreeFrog have emerged as a potential solution as the microtissue is in itself a network, providing protection to the cells and facilitating transplantation.
Peter Andersen, Chief R&D Officer, TreeFrog Therapeutics commented 'I am excited to present, for the first time, a validated delivery strategy for a 3D microtissue format cell therapy. The development took 4 years, and I am proud of what the cross-functional team has achieved. 3D formats have huge potential, but the team also had to overcome challenges such as faster sedimentation to ensure homogenization and accurate dose delivery. The team also focused on developing a device using existing components which will facilitate education of use for neurosurgeons and their teams.'
To learn more about this delivery strategy, those attending the ASGCT can attend the poster session and exchange with Peter Andersen:
Venue: On-site Poster Hall
Title: Development of a Delivery Strategy for Neural Microtissues in Parkinson's Disease Cell Therapy (#2039)
Link to Late-Breaking Abstracts ASGCT Abstracts
About TreeFrog Therapeutics
TreeFrog Therapeutics is a French-based regenerative medicine biotech set to unlock access to cell therapies for millions of patients with a lead program in Parkinson's disease. TreeFrog is unique in its approach to cell therapy development, bringing together biophysicists, cell biologists and bioproduction engineers to address the challenges of the industry - producing and differentiating cells of quality at unprecedented scale, cost-effectively. To succeed in their mission of Cell Therapy for all, TreeFrog operates a business model that includes its own therapeutic programs and partnerships with leading biotech and industry players. Since 2021, the company has raised $82 million to advance a pipeline of stem cell-based therapies in regenerative medicine.
1
2 Su D et al. Projections for prevalence of Parkinson's disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021. BMJ. 2025;388:e080952
3
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Buzz Feed
40 minutes ago
- Buzz Feed
Take On Me Singer Morten Harket Said He Has Parkinson's Disease
Morten Harket, who for more than 40 years has been the frontman of the Grammy-nominated Norwegian pop trio a-ha, confirmed this week that he has Parkinson's disease. Harket, 65, made the announcement Wednesday by sharing an article written by music journalist and author Jan Omdahl on a-ha's official website. In it, the singer-songwriter said he'd been experiencing vocal issues as a result of his condition, and admitted he was unsure about a return to the concert stage. 'The problems with my voice are one of many grounds for uncertainty about my creative future,' he said. Though Harket said he had 'no problem accepting the diagnosis,' he added, 'I'm trying the best I can to prevent my entire system from going into decline. It's a difficult balancing act between taking the medication and managing its side effects. There's so much to weigh up when you're emulating the masterful way the body handles every complex movement, or social matters and invitations, or day-to-day life in general.' A native of Kongsberg, Norway, Harket formed a-ha with keyboardist Magne Furuholmen and guitarist Paul Waaktaar-Savoy in 1982. Three years later, the band catapulted to international fame with their breakout smash, ' Take On Me.' The song's success was buoyed by its now-iconic music video, which combined live-action performance footage with pencil-sketch animation. Though a-ha never replicated the success of 'Take On Me' on a global scale, the band continued to release music throughout the '80s and '90s. In 1991, they broke the world record for paid attendance at a rock concert when they performed before more than 198,000 fans at Brazil's Rock in Rio festival. Their 11th studio album, True North, was unveiled in 2022. There is no cure for Parkinson's, a neurodegenerative disease that can cause muscle stiffness, impaired speech and uncontrolled movement. The disease can be revealed by a mere tremor of the hand, according to the Mayo Clinic. Furuholmen reacted to Harket's announcement with a heartfelt post on Instagram. Acknowledging he'd known about his bandmate's diagnosis 'for some time,' he said the news 'brings sadness,' but stressed 'there is also a lot of gratitude: for all the amazing memories, for how our combined creative efforts as a band have been so generously embraced by the world, and for how lucky we are that people continue to find meaning, hope and joy in our shared musical legacy.' In his chat with Omdahl, Harket said he didn't expect to regain 'full technical control' over his vocals, but had nonetheless been working on new songs 'that I've got great belief in, and I feel the lyrics, especially, have something of a different aspect of me in them.' United Archives / United Archives via Getty Images 'I'm not sure if I'll be able to finish them for release,' he continued. 'Time will tell if they make it. I really like the idea of just going for it, as a Parkinson's patient and an artist, with something completely outside the box. It's all up to me, I just have to get this out of the way first.'
Yahoo
an hour ago
- Yahoo
Trump to slash funding for flagship US HIV programme by 40pc
America is proposing to cut its flagship anti-HIV programme by almost 40 per cent next year, according to new budget details that reveal sweeping reductions to global health spending. Details from Donald Trump's 2026 budget request show nearly a two-fifths fall in funding for the United States President's Emergency Plan for Aids Relief (Pepfar). The long-running programme is estimated to have saved more that 20 million lives in the past two decades, and is often cited as one of the world's most successful public health schemes. A recent analysis published in the Lancet found that as many as half a million more children could die from Aids by the end of the decade because of disruptions to Pepfar. The details on global health funding for the State Department, USAID agency, Centres for Disease Control and Prevention (CDC), and the National Institutes of Health (NIH) also show deep cuts elsewhere. Analysis by the San Francisco-based KFF health policy charity found the government departments were planning a 55 per cent cut in separate tuberculosis funding, a 47 per cent cut in malaria funding and a 92 per cent cut in maternal health funding. The proposal also withdraws all £221m ($300m) given to Gavi, the vaccine alliance which provides jabs to children in poor countries. In total, the request for money for the American government's main global health funding account is £2.8bn ($3.8bn) in 2026, down from £7.4bn ($10bn) in 2025. Setting out the cuts, the State Department said the request for money 'eliminates funding for programmes that do not make Americans safer, such as family planning and reproductive health, neglected tropical diseases, and non-emergency nutrition'. Mr Trump's government upended US aid spending days after taking office, saying it would suspend all aid while projects were reviewed. It then proceeded to close hundreds of aid programmes, including Pepfar projects, resulting in lay-offs for thousands of health workers, particularly in Africa. The budget proposals now give a clear indication that Mr Trump intends to continue with sharp cuts and will quash any hopes that the funding taps could be switched back on again. A State Department explanation of the budget request uses the phrase 'America First' 37 times as it explains a new focus on cutting costs and protecting US national interests. For the 2026 fiscal year, which begins on Oct 1, the budget proposals request £2.1bn ($2.9bn) for Pepfar, a 38 per cent reduction from the £3.5bn ($4.7bn) requested in 2025. The State department said that after spending a total of £88bn ($120bn) in the past two decades, it was now focussing on finding a responsible 'off ramp' to hand over responsibility for the campaign against HIV to countries themselves. 'This [budget] request will allow the United States to accelerate the transition of HIV control programmes to recipient countries and increase international ownership of efforts to fight HIV/Aids.' Some projects may still be paid for by other government funds, but overall the KFF analysis found the budget included 'significant reductions in global health funding including the elimination of some programs and activities'. The details will prove a severe disappointment to aid projects who had hoped that despite Mr Trump's rhetoric, there was a chance funding could be renewed in the new fiscal year. Public health officials argue that continuing to fund global health projects to stamp out infectious diseases is still in America's best interests as infections often cross borders. One executive at a major South African anti-HIV organisation said: 'Nobody wins unless we all win. No one can make it out of this alone. This is how we achieve epidemic control.' Protect yourself and your family by learning more about Global Health Security Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Business Wire
an hour ago
- Business Wire
Elion Launches Integration of Coalition for Health AI ‘Nutrition Label' Within Vendor Marketplace
NEW YORK--(BUSINESS WIRE)--Elion, the healthcare technology research and intelligence platform for the AI era, announced today a new partnership with the Coalition for Health AI (CHAI), an industry-led coalition committed to developing industry best practices and frameworks to further innovation, safety and security for health AI. As part of this partnership, Elion is beta-launching a new feature: Abridged CHAI model cards now appear on select vendor profiles across its platform. 'As demand for AI adoption accelerates, healthcare leaders need a shared language and set of standards to evaluate solutions responsibly." To facilitate robust evaluation and accelerate adoption of successful AI solutions, CHAI developed an Applied Model Card framework, and recently established its first Model Card registry to support the rapid growth of model cards, or 'nutrition labels' for health AI, used to simplify procurement among health systems and solution providers. CHAI's model cards have created a more standard way to present foundational information about AI solutions, moving from powerpoint presentations to evidence and value-based procurement. Elion cofounder and CEO, Bobby Guelich, announced this new functionality at the CHAI Innovation Summit this week. Providing availability of CHAI's Model Cards through the Elion platform helps provider organizations quickly assess an AI model's intended use, oversight processes, and key performance considerations—all in the context of Elion's broader research and marketplace infrastructure. 'As demand for AI adoption accelerates, healthcare leaders need a shared language and set of standards to evaluate solutions responsibly,' said Guelich. 'CHAI's work in this area is foundational, and we're excited to bring their model cards into the day-to-day workflows of technology decision-makers through Elion's marketplace.' This integration represents the latest step in Elion's mission to equip health systems with the data, tools, and guidance needed to evaluate and implement emerging technologies. The current version includes model cards for a limited set of vendor solutions, with broader availability planned later this year. 'I am thrilled to see our health AI nutrition label advancing effective and responsible health AI,' said Brian Anderson, CHAI's CEO. 'By integrating this with Elion, we are enabling health system AI solution evaluation and allowing decision-makers to easily access Model Cards. CHAI is driven by the expertise of our members and the feedback of our broader health ecosystem and the public. We look forward to working together to unlock the potential benefits of AI, on a foundation of trust, safety, and security." CHAI model cards were designed to enhance transparency and accountability across the AI lifecycle. By displaying key elements of these cards on vendor profiles, Elion aims to bridge the gap between technical documentation and real-world procurement. Learn more about CHAI model cards here. About Elion: Elion is a trusted health IT marketplace and research firm dedicated to empowering healthcare organizations through technology insights and strategic guidance. By bridging the gap between healthcare leaders and innovative solutions, Elion is driving the future of healthcare delivery. For more information, visit: About CHAI: The CHAI (Coalition for Health AI) mission is to be the trusted source of guidelines for Responsible AI in Health. It aims to ensure high-quality care, foster trust among users, and meet the growing healthcare needs. As a coalition bringing together leaders and experts representing health systems, startups, government and patient advocates, CHAI has established working groups focusing on privacy and security, fairness, transparency, usefulness, and safety of AI algorithms.
